Your browser doesn't support javascript.
loading
In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii.
Michaeli, Janna; Mandel, Shira; Maximov, Shelly; Zazoun, Jonathan; Savoia, Paola; Kothari, Nimmi; Valmont, Thomas; Ferrari, Livia; Duncan, Leonard R; Hawser, Stephen; Cohen-Kutner, Moshe; Bachnoff, Niv.
Afiliação
  • Michaeli J; Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel.
  • Mandel S; Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel.
  • Maximov S; Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel.
  • Zazoun J; Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel.
  • Savoia P; Evotec Anti-Infective, Department of Microbiology Discovery, Aptuit (Verona) Srl, an Evotec Company, Via A. Fleming 4, 37135 Verona, Italy.
  • Kothari N; IHMA Europe Sàrl, Route de l'Ile-au-Bois 1A, 1870 Monthey, Switzerland.
  • Valmont T; IHMA Europe Sàrl, Route de l'Ile-au-Bois 1A, 1870 Monthey, Switzerland.
  • Ferrari L; Evotec Anti-Infective, Department of Microbiology Discovery, Aptuit (Verona) Srl, an Evotec Company, Via A. Fleming 4, 37135 Verona, Italy.
  • Duncan LR; JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
  • Hawser S; IHMA Europe Sàrl, Route de l'Ile-au-Bois 1A, 1870 Monthey, Switzerland.
  • Cohen-Kutner M; Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel.
  • Bachnoff N; Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel.
Antibiotics (Basel) ; 11(9)2022 Sep 05.
Article em En | MEDLINE | ID: mdl-36139979
ABSTRACT
The rapid worldwide spread of antimicrobial resistance highlights the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. This study describes the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii clinical isolates. OMN6 prevented the growth of all tested isolates, regardless of any pre-existing resistance mechanisms. Moreover, in vitro serial-passaging studies demonstrated that no resistance developed against OMN6. Importantly, OMN6 was highly efficacious in treating animal models of lung and blood infections caused by multidrug-resistant A. baumannii. Taken together, these results point to OMN6 as a novel antimicrobial agent with the potential to treat life-threatening infections caused by multidrug-resistant A. baumannii avoiding resistance.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article